Clinical trials: Refractory Status Epilepticus
Status Epilepticus
Sustained Effort Network for Treatment of Status Epilepticus/European Academy of Neurology Registry on Refractory Status Epilepticus (SENSE-II/AROUSE)
SENSE-II/AROUSE is a prospective, multicenter registry for patients treated for SE. The primary objective is to document patients and SE characteristics, treatment modalities, EEG features, and outcome of consecutive adults…
- Trial name
- SENSEII/AROUSE (NCT05839418)
- Where
- 11 sites in Austria, Belgium and 6 more
- Volunteers
- 3,000 people
- Sponsor
- Erasme University Hospital
Status Epilepticus, Seizure
Ketogenic Diet for Refractory Status Epilepticus
This research is being done to observe the safety, tolerability, side effects, and effectiveness of the ketogenic diet in people with continuous seizures (status epilepticus) being treated in a neurointensive care unit.
- Conditions
- Status Epilepticus, Seizure, Epilepsy, Refractory Status Epilepticus
- Trial name
- NCT01796574
- Testing
- Ketogenic diet
- Where
- 9 sites in United States
- Volunteers
- 15 people
- Sponsor
- Johns Hopkins University
Refractory Status Epilepticus
Application of tDCS Stimulation in Controlling Refractory Status Epilepticus
The purpose of the study is to assess the efficacy and safety of targeting tDCS stimulation for treatment of Refractory status epilepticus
- Trial name
- tDCS (NCT06344338)
- Testing
- tDCS stimulation
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Xuanwu Hospital, Beijing
Mitochondrial Diseases, Drug Resistant Epilepsy
A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy
This is a parallel-arm, double-blind, placebo-controlled study with a screening phase that includes a 28-day run-in phase to establish baseline seizure frequency, followed by a 24-week, randomized, placebo-controlled phase.
- Conditions
- Mitochondrial Diseases, Drug Resistant Epilepsy, Leigh Disease, Leigh Syndrome
- Trial name
- MIT-E (NCT04378075)
- Testing
- Vatiquinone
- Where
- 27 sites in United States, Canada and 7 more
- Volunteers
- 68 people
- Sponsor
- PTC Therapeutics
Refractory Status Epilepticus
Ketamine for the Treatment of Refractory Status Epilepticus
This pilot feasibility study aims to examine how the timing of ketamine introduction as a third-line anti-seizure medication infusion relates to seizure cessation in patients with refractory status epilepticus (RSE).
- Trial name
- NCT07177235
- Testing
- Ketamine, Midazolam
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Thomas Jefferson University
Status Epilepticus
Treatment of Refractory Status Epilepticus
The purpose of this study is to determine whether propofol or barbiturates should be preferred in the treatment of status epilepticus (continuous seizure activity) refractory to 2 standard antiepileptic agents.
- Trial name
- NCT00265616
- Testing
- propofol, thiopental/pentobarbital
- Where
- 5 sites in United States, Switzerland
- Volunteers
- 23 people
- Sponsor
- Brigham and Women's Hospital
Epilepsia Partialis Continua, Status Epilepticus
Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Epilepsy
The purpose of this study is to assess the effects of repetitive transcranial magnetic stimulation (rTMS) as a treatment for Epilepsia Partialis Continua (EPC) or refractory Status Epilepticus (SE), when standard clinical…
- Trial name
- NCT02560597
- Testing
- repetitive transcranial magnetic stimulation
- Where
- Belgium
- Volunteers
- 4 people
- Sponsor
- University Hospital, Ghent
Refractory Epilepsy
Efficacy of Ketamine Infusion Compared With Traditional Anti-epileptic Agents in Refractory Status Epilepticus
The study will investigate the efficacy of the N-methyl-D-aspartate receptor antagonist ketamine as a first line agent in refractory status epilepticus versus traditional general anesthetic agents used for burst suppression that…
- Trial name
- NCT03115489
- Testing
- Traditional Treatment (Group T), Ketamine Infusion (Group K)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Status Epilepticus, Refractory Status Epilepticus
Refractory Status Epilepticus Treatment: Quality and Efficacy of Coma Induction
This study is to investigate the effects of different treatment characteristics regarding the use of intravenous anesthetic drugs (IVADs) as a rescue treatment for refractory Status epilepticus (RSE) on course and outcome.
- Trial name
- RESET (NCT04333082)
- Testing
- Data collection
- Where
- Switzerland
- Volunteers
- 147 people
- Sponsor
- University Hospital, Basel, Switzerland
Refractory Status Epilepticus
Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus
This project is aiming to better understand the use of perampanel as an appropriate standard-of-care therapy for treatment refractory status epilepticus (RSE), to identify determinants of outcomes, and establish safety.
- Trial name
- NCT05684978
- Testing
- Perampanel
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Wayne State University
New Onset Refractory Status Epilepticus, New-Onset Refractory Status Epilepticus
COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE"
The goal of this clinical trial is to find out whether two existing medications-anakinra and tocilizumab-can effectively treat a rare and life-threatening brain condition called NORSE (New-Onset Refractory Status Epilepticus).
- Conditions
- New Onset Refractory Status Epilepticus, New-Onset Refractory Status Epilepticus, Febrile Infection-Related Epilepsy Syndrome (FIRES)
- Trial name
- COMBAT-NORSE (NCT07281027)
- Testing
- Anakinra, Tocilizumab, Standard medical treatment
- Where
- 33 sites in United States, Canada and 5 more
- Volunteers
- 438 people
- Sponsor
- Yale University
Status Epilepticus
Stiripentol for the Treatment of Refractory Status Epilepticus
The investigators retrospectively analyzed all patients who were admitted to the Department of Neurology at Marburg University Hospital between 2013 and 2023 with a diagnosis of (super)-refractory status epilepticus and who…
- Trial name
- NCT06540378
- Testing
- Stiripentol
- Volunteers
- 25 people
- Sponsor
- University Hospital Marburg
Epilepsy
Possible Immuno-Modulatory Effect of Tocilizumab in Patients With Refractory Status Epilepticus.
Recently, the pathogenesis of epilepsy is immuno-modulatory and neuro-inflammatory which is commonly activated in epileptogenic brain regions in humans and is clearly involved in animal models of epilepsy.
- Trial name
- NCT05346666
- Testing
- Tocilizumab Prefilled Syringe [Actemra]. propofole, phenobarbital, midazolam
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Damanhour University
Hypoxia-Ischemia, Brain, Heart Arrest
buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest
RESTORE is a randomized clinical trial investigating the safety and feasibility of using EEG treatment targets (burst suppression vs. seizure suppression) for post-cardiac arrest refractory status epilepticus treatment.
- Conditions
- Hypoxia-Ischemia, Brain, Heart Arrest, Status Epilepticus, Refractory Status Epilepticus
- Trial name
- RESTORE (NCT05851391)
- Testing
- Burst Suppression EEG Target Intravenous Anesthesia, Seizure Suppression EEG Target Intravenous Anesthesia
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Francisco
Epilepsy, Status Epilepticus
Repeated TMS at Low Frequencies to Reduce Seizure Occurrence
Perform non-invasive neuro-navigated repeated Transcranial Magnetic Stimulation (rTMS) at low frequencies (LF) with the intent to reduce the occurrence of seizures over time (long-term protocol).
- Conditions
- Epilepsy, Status Epilepticus, Epilepsia Partialis Continua, Epilepsia Partialis Continua, Refractory (Medically)
- Trial name
- NCT03154307
- Testing
- Low frequency repeated TMS (LF-rTMS)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Baptist Health South Florida
Super-refractory Status Epilepticus
KD Treatment for Super-refractory Status Epilepticus
The purpose of the study is to investigate to evaluate the efficacy and safety of ketogenic diet (KD) as an adjunctive therapy in patients with Super Refractory Status Epilepticus (SRSE) in the intensive care unit (ICU).
- Trial name
- KD (NCT07496749)
- Testing
- the ketogenic diet, Standard Medical Therapy
- Where
- 14 sites in China
- Volunteers
- 84 people
- Sponsor
- Xuanwu Hospital, Beijing
Status Epilepticus
SURESTEP: Transcranial Direct Current Stimulation in Super Refractory Status Epilepticus
The purpose of this study is to determine whether transcranial direct current stimulation affects super refractory status epilepticus.
- Trial name
- SURESTEP (NCT03819543)
- Testing
- Transcranial Direct Current Stimulation
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- University of Manitoba
Super-refractory Status Epilepticus
Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus
The purpose of this study is to evaluate the safety and tolerability of SAGE-547 in participants in super-refractory status epilepticus (SRSE).
- Trial name
- SRSE (NCT02052739)
- Testing
- SAGE-547
- Where
- 17 sites in United States
- Volunteers
- 25 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Status Epilepticus
Ketamine in Refractory Convulsive Status Epilepticus
To evaluate the efficacy of intravenous administration of ketamine in the treatment of refractory convulsive status epilepticus in children compared to administration of midazolam at high doses, thiopental and / or propofol.
- Trial name
- KETASER01 (NCT02431663)
- Testing
- Ketamine
- Where
- Italy
- Volunteers
- 57 people
- Sponsor
- Meyer Children's Hospital IRCCS
Super-Refractory Status Epilepticus
An Open Label, Expanded Access Protocol With SAGE-547 for Super-Refractory Status Epilepticus
This is an open-label, expanded access protocol, designed to offer treatment with SAGE-547 to subjects in SRSE, and to evaluate the efficacy and safety of SAGE-547 administered as a continuous intravenous infusion to these…
- Trial name
- NCT02433314
- Testing
- SAGE-547
- Sponsor
- Supernus Pharmaceuticals, Inc.